A Phase 1 Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of ASP2215

Next Previous
Trial Profile

A Phase 1 Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of ASP2215

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Mar 2016

At a glance

  • Drugs Gilteritinib (Primary)
  • Indications Acute myeloid leukaemia; Non-small cell lung cancer
  • Focus Pharmacokinetics
  • Sponsors Astellas Pharma

    • Most Recent Events

    • 17 Mar 2016 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
    • 26 Oct 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 15 Oct 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top